00:00The field of lymphoma diffuse cell is evolving very, very quickly with a whole series of
00:09innovative drugs that are being supported, even in some cases replacing chemotherapy.
00:15Among these, we remember the CAR-T cells, cells armed against lymphoma tumor cells,
00:21extremely powerful, but also all the new monoclonal antibodies, some of which act
00:26by stimulating the immune system to hit the lymphoma, like the more specific antibodies,
00:32others that carry out their effectiveness by bringing toxins, therefore poisonous and toxic substances,
00:39directly against the tumor cell, such as, for example, ipoilatuzumab and oncastuzumab.
00:44These are all extremely important and effective approaches that we must learn to know, develop, combine.
00:52Therefore, a vast field of research is opening up, which is certainly bringing, and will continue to bring,
00:58more and more important benefits for patients.
01:00The unmet needs are linked to the fact that these therapeutic devices must be integrated,
01:06combined and used better.
01:08So we have to learn to use what we already have best and, of course, we also have to develop
01:13some new treatments, new potentials, because there are certainly some particularly difficult patients,
01:20those who have the IP53 mutation or those who have certain genetic alterations that make them
01:25particularly resistant to the death induced by the treatments.
01:30We still need to work on this.
01:32In this, a combination of biological studies is very important, which allows us to better know
01:39the differences between various lymphomas and the use of new molecules in the context of well-conducted clinical experiments.
Comments